key: cord-1000582-jm2c3mqv authors: Mennini, Francesco S.; Marcellusi, Andrea; Robbins Scott, Sarah; Montilla, Simona; Craxi, Antonio; Buti, Maria; Gheorghe, Liana; Ryder, Stephen; Kondili, Loreta A. title: The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries date: 2021-02-24 journal: Liver Int DOI: 10.1111/liv.14808 sha: b15db8cec788587c261464aea5d4b0cff689fbcb doc_id: 1000582 cord_uid: jm2c3mqv BACKGROUND AND AIMS: We assessed the clinical and economic impact of direct‐acting antiviral (DAA) therapy for hepatitis C virus (HCV) in England, Italy, Romania and Spain. METHODS: An HCV progression Markov model was developed considering DAA eligibility and population data during the years 2015‐2019. The period of time to recover the investment in DAAs was calculated as the cost saved by avoiding estimated clinical events for 1000 standardized treated patients. A delayed treatment scenario because of coronavirus disease (COVID‐19) was also developed. RESULTS: The estimated number of avoided hepatocellular carcinoma, decompensated cirrhosis and liver transplantations over a 20‐year time horizon was: 1,057 in England; 1,221 in Italy; 1,211 in Romania; and 1,103 in Spain for patients treated during 2015‐2016 and 640 in England; 626 in Italy; 739 in Romania; and 643 in Spain for patients treated during 2017‐2019. The cost‐savings ranged from € 45 to € 275 million. The investment needed to expand access to DAAs in 2015‐2019 is estimated to be recovered in 6.5 years in England; 5.4 years in Italy; 6.7 years in Romania; and 4.5 years in Spain. A delay in treatment because of COVID‐19 will increase liver mortality in all countries. CONCLUSION: Direct‐acting antivirals have significant clinical benefits and can bring substantial cost‐savings over the next 20 years, reaching a Break‐even point in a short period of time. When pursuing an exit strategy from strict lockdown measures for COVID‐19, providing DAAs should remain high on the list of priorities in order to maintain HCV elimination efforts. Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality worldwide. 1, 2 The effect of antiviral therapy, in terms of the impact on clinical-related outcomes rather than virological efficacy, changes over time according to the epidemiological profile of the disease, specific patient characteristics including fibrosis stage, and antiviral treatment efficacy. [3] [4] [5] [6] [7] These factors vary by country, meaning country-specific epidemiology of HCV infection, DAA treatment guidelines, and treatment access are expected to impact the burden of HCV-liver related outcomes following viral eradication. No clinical studies have assessed the impact of antiviral therapy on long-term morbidity and mortality, however, as it is unethical to maintain patients without therapy. Thus, only a modelling approach can address this issue and predict its impact on a population. 5 In this study, we built country-specific models using real-life data of fibrosis stage, genotype distribution and treatment eligibility for A country-specific Markov model was designed to estimate the clinical and economic outcomes of expanded access to DAA therapy, considering the direct costs of HCV treatment in the European context (England, Italy, Romania and Spain). The model inputs are shown in Tables 1 and 2. • Despite the country-specific dynamics and natural history of hepatitis C virus (HCV) infection in Italy, Spain, Romania, and England, expanding access to treatment will lead to a positive return on investment and is cost saving in <10 years. • Not treating or delaying treatment of infected individuals will result in higher disease burden and costs, which could be avoided with immediate screening, linkage to care, and treatment of all HCV infected individuals. • As lockdown orders for coronavirus disease 2019 (COVID-19) begin to lift, providing direct acting antivirals (DAAs) should remain a priority for public health officials in order to maintain HCV elimination efforts. Conclusion: Direct-acting antivirals have significant clinical benefits and can bring substantial cost-savings over the next 20 years, reaching a Break-even point in a short period of time. When pursuing an exit strategy from strict lockdown measures for COVID-19, providing DAAs should remain high on the list of priorities in order to maintain HCV elimination efforts. break-even, DAAs, HCV elimination, hepatitis C infection TA B L E 1 Transition probabilities and efficacy of treatment (base-case, deterministic and probabilistic sensitivity analysis parameters) Base-case Parameter value used in the DSA [11] Standard error included in the PSA Source F0 to F1 0.117 0.113 0,010 [12] F1 to F2 0.085 0.113 0,007 [12] F2 to F3 0.120 0.113 0,010 [12] F3 to F4 0.100 0.113 0,009 [13] F4 to decompensated cirrhosis (DC) 0.030 0.041 0,003 [13] F4 to HCC 0.050 0.021 0,004 [13] Decompensated cirrhosis to HCC 0.100 0.014 0,009 [13] Decompensated cirrhosis to transplant 0.110 0.031 0,009 [13] HCC to transplant 0.200 0.031 0,017 [14] SVR to HCC a 0.008 0.009 0,000 Assumption from [15] SVR to transplant a 0.016 0.020 0,002 Assumption from [15] Annual probability of progressing to death Base-case Decompensated cirrhosis to death (liver-related) 0.090 0.221 0,008 [15] HCC to death (liver-related) 0.430 0.221 0,037 [14] Transplant (procedure) to death (liver-related) 0.150 0.1715 0,013 [14] Transplant (following years) to death (liver-related) 0.057 0.0353 0,005 [14] Death from all other causes Italy [16] The probabilities of progressing through the various stages of disease were based on the results of a literature review ( All transition probabilities are adjusted for competing probabilities of death from other causes according to the official data from each country (Supporting Information Table A1 ). 16 For the HCC state, the probability of death because of HCV and the probability of transplant were assumed to be independent. The model simulates a cohort of 1000 standardized treated patients according to real-life fibrosis stage and genotype distribution data for England, Italy, Romania and Spain. 19-23 Fibrosis stage by age and genotype distribution of treated patients by year for each of the countries included in the study were collected. The fibrosis distribution of treated patients for each country is reported in Figure 1 , while the genotype distribution for each country during the two time periods evaluated is shown in Table A2 outcomes were compared to a cohort of non-treated patients. The efficacy of second-generation DAA regimens used in each period was stratified by genotype distribution and the presence or absence of cirrhosis (F0-F4, DC or HCC), as summarized in Table 1 and Tables A3-A5 in the Supporting Information 3 The model simulates two different scenarios considering 1000 standardized patients over a 20-year time horizon: Direct healthcare costs were those associated with the manage- (Table 2) . 10, 17, 24, 29 The average treatment cost of DAAs was estimated based on expert opinion and non-official sources. The associated per-patient cost by disease stage post-SVR was assumed to be null, presuming a state of full health after SVR for the patient until F3 fibrosis stage (Table 2 and Supporting Information Figure A1 ). The associated per-patient cost by disease stage post-SVR from ILD remained associated to the costs of ILD prior to therapy, independently of the achievement of SVR (Table 2) Costs were expressed in Euros and were discounted at a rate of 3% annually. To estimate the uncertainty of the economic results, probabilistic sensitivity analysis (PSA) and deterministic sensitivity analysis (DSA) were performed. The probabilistic distribution choice for cost was made by applying a gamma distribution and for epidemiological parameters, a beta distribution. 30 Tables 1 and 2 A delayed treatment scenario because of the COVID-19 pandemic was developed to estimate the incremental cases associated with the subsequent scenario: 1. Base-case 2020: all patients were treated during the first year and followed for 5 years; Spain and Italy, but only a 25% increase in Romania. (Figure 1 ). By expanding access to DAA therapies in 2017-2019, the model es- In all countries, it would take less than 10 years to reach a Breakeven point (Table 3) Considering the confidence intervals around the base case values (Table 3) As shown in Figure 4 , there will be a progressive increase in HCV disease-related outcomes because of the delay in treatment caused by COVID-19. Generally, there will be an increase in the number of As COVID-19 has become a global pandemic, we considered the impact that the disease may having on delaying access to DAA therapy. Despite major differences in HCV epidemiology and disease burden among the evaluated countries, the delayed treatment scenario generates comparable liver related mortality in the four countries evaluated. Over time, severe clinical outcomes because of delayed treatment will be evident in England, Spain and Romania, which will however result in less mortality than seen in Italy. In these three countries, while progressive liver disease will be evident across the next 5 years if treatment is delayed, the HCV infected population, as seen by the treatment data, is more likely to be in earlier stages of disease. On the contrary, in Italy, the liver morbidity is generally equal to the liver mortality because among individuals who WHO. Global Health Sector Strategy on Viral Hepatitis Towards Ending Viral Hepatitis. World Health Organization Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study EASL recommendations on treatment of hepatitis C 2018 HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality Predicted effects of treatment for HCV infection vary among European countries Chronic hepatitis C virus (HCV) disease burden and cost in the United States Global timing of hepatitis C virus elimination in high-income contries The economic burden of HCVinduced diseases in Italy. A probabilistic cost of illness model Early treatment in HCV: is it a cost-utility option from the Italian perspective? Economic consequences of investing in anti-HCV antiviral treatment from the italian nhs perspective: a real-world-based analysis of PITER data Cost-effectiveness of antenatal rescreening among pregnant women for hepatitis C in the United States Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a metaanalysis and meta-regression A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies Lifetable from European Countries Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: interim evaluations from the PITER network Local data from the NHS England Nottingham Hepatitis C operational Delivery Network Aggiornamentio dati Registri AIFA DAAs, epatitie C cronica Therapeutic Protocol for Patients with HCV Chronic Hepatitis and Cirrhosis Treated with Interferon-free Direct-Acting Antivirals Strategic plan for tackling hepatitis c in the spanish national health system Estimating the costeffectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus Management of treatmentnaive chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options Burden of hepatitis C in Europe-the case of France and Romania. Presented to: European Liver Patients Association Cost-utility analysis of triple therapy with tela-previr in treatment-naïve hepatitis C patients Análisis costeefectividad de dos estrategias de tratamiento para la hepatitis C crónica: antes y después del acceso a los agentes antivirales de acción directa en España. Gastroenterología y Hepatología Costeffectiveness analysis of sofosbuvir-based regimens for chronichepatitis C Decision modelling for health economic evaluation Will the COVID-19 pandemic affect HCV disease burden? Correspondence/Dig Liver Dis Declining prevalence and increasing awareness of hepatitis C virus infection in Italy: a population -based survey HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications Seroepidemiologic study of hepatitis C virus infection in a general population from the region of La Rioja The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey Hepcare Europe bridging the gap in the treatment of hepatitis C: study protocol Clinical outcomes after transfusion-associated hepatitis C Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicentre study The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre Improving the accuracy of long-term prognostic estimates in hepatitis C virus infection Cost-effectiveness Analysis of Daclatasvir/Sofosbuvir for the Treatment of the HCV Patients Failed After the First Line With Second Generation of DAAs in Italy Optimization of hepatitis C virus screening strategies by birth cohort in Italy Estimated prevalence of undiagnosed HCV infected individuals in Italy: a mathematical model by route of transmission and fibrosis progression investment and expanding access to treatment is cost saving in less than 10 years in the countries analysed. Universal access to therapies in all infected individuals will result in stronger economic returns and less disease burden. It should be noted though, as depicted in the delayed treatment scenario, that not treating or delaying treatment of infected individuals will result in higher disease burden and consecutively higher costs for the NHS. Policy makers could consider these efforts when determining the most cost-effective methods for managing HCV infection across Europe. As lockdown measures for COVID-19 begin to lift, providing DAAs should remain high on the list of priorities for public health officials in order to maintain HCV elimination efforts.